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Abstract 
In part one, we simulated a successive of two-armed randomized clinical trial with 
the time-to-event outcome over 15 years. We used three different accrual pattern 
representing slow, medium and fast accrual, which is in fact related to the number of 
trials for the sequential trials interested in the 15-year period. We used a historical 
survival distribution to explore the treatment effects and analyzed by the Cox 
proportional hazard ratio model and log-rank test. We computed the mean and median 
overall hazard ratio (year 15 versus year 0), and the probability of detrimental effect to 
find the optimal design parameters. Finally, we carried out a sensitivity analysis to study 
the effect of an additional 6 month turnaround time.  
In Part two, we have described a general workflow for the normalization of ChIP-
seq data by estimating the normalization factor from peak-less regions. Using publicly 
available histone 3 lysine 36 trimethylation (H3K36me3) data from human kidney cancer, 
we demonstrated the better performance of our method over the existing approach. 
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Part I  A Simulation Study of Patient Accrual Patterns in 
Clinical Trials  
I-1  INTRODUCTION 
 Clinical trials have played an important role in the development of drugs or 
treatments, which is a time consuming and expensive process.1 It usually involves 
recruiting subjects, designing treatment strategy, collecting data and evaluating the results. 
Sample size estimation and recruitment are the most fundamental parts of the research 
design and determine the success of the trial to a large extent. It has been reported that 
clinical trials fail due to inefficient and insufficient patient recruitment process.2   
 Survival analysis compares the treatment effects between the control and the 
experimental groups at multiple points in time.3 A special case is the oncology clinical 
trial. For this kind of disease, it is more difficult to recruit enough people than for other 
diseases over a long-term research period.4 A small gain in survival is considered as 
clinically relevant. To distinguish this subtle difference, a much larger sample size is 
required. These two factors make clinical trials with large sample size less practical. In 
response to the complexity of the clinical trial design and the occurrence of clinical trial 
failures, clinical trial simulation (CTS) based on known knowledge has been applied to 
model a clinical trial under the different trial scenarios and assess the probability of a 
successful outcome since the late twentieth century.5 The merit of the CTS lies in its 
high efficiency, low cost and flexible adjusting of different trial scenarios and related 
design parameters for unlimited number of trials with reliable knowledge inherited from 
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historical clinical trial analysis.6 For example, Strauss and Simon proposed a process for 
clinical trials that has a limited number of patients available for treatments over a period. 
Instead of a single trial, they considered to carry out a sequential two-armed randomized 
clinical trials. In the end, they choose an optimal treatment based on the expected success 
probability.7 Later Sposto and Stram pioneered a simulation on pediatric cancer trials 
with smaller sample sizes in a survival analysis setting.8 They investigated the treatment 
efficacy of factors like trial duration, significance level, patient accrual rate, and sample 
size in a series of two-treatment randomized trials. They found that larger α level and a 
series of smaller trials in a 25-year research course afforded larger average gains in cure 
rate. Deley and Ballman further expanded this strategy by carrying out more trials 
(smaller) in different accrual patterns with different evaluation criteria over a 15-year 
horizon.9 Their findings implied that both the significance level and the number of trials 
(related to the sample size) played a role in the treatment effect when trials with smaller 
sample size were performed. 
 In this research, we simulated a successive two-armed randomized clinical trial 
with the time-to-event outcome over 15 years. We used three different accrual pattern 
representing slow, medium and fast accrual, which is in fact related to the number of 
trials for the sequential trials interested in the 15-year period. We used a historical 
survival distribution to explore the treatment effects and deployed the Cox proportional 
hazard ratio model and log-rank test for analysis. We computed the mean and median 
overall hazard ratio (year 15 versus year 0), and the probability of detrimental effect to 
find the optimal design parameters. Finally, we carried out a sensitivity analysis to study 
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the effect of an additional 6 month turnaround time. The practical utility of this strategy 
lies in that with the development of molecular genetics and next generation sequence 
technology, many cancers originally thought to be the same type now are found having 
multiple rarer sub-types. Our method provides an insight on how to carry out clinical 
trials in this new era. 
I-2   METHODS 
 Our current study is based on the theory of survival analysis. We assume that trials 
are performed in a series of two-treatment randomized clinical trials (control treatment as 
the current standard of care versus new experimental treatment.). Each trial has an 
accrual period and a fixed follow-up time (FU) before the start of the next trial, which 
will be compared with the current standard treatment. The one with a better treatment 
effect will be used in the next randomized trial. This cycle was repeated until the last trial 
reached the end of the 15th year with overall survival as the primary endpoint. Simulation 
parameters include different trial sample sizes, accrual rates, and distributions of 
treatment effect. 
I-2.1  Simulation parameters and statistical formulation 
Sample size n 
 For each trial, the sample size n was a constant throughout the simulated successive 
trials. We will consider ten different sample sizes, which increased from 100 patients to 
1000 patients in our trials. 
Accrual rate η 
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 Accrual rate η is the number of patients accrued per year. We will consider three 
different accrual rates in our study: 100, 200, and 500 patients/year. 
Accrual period TAcc 
 Accrual period TAcc refers to the length of time required to obtain the desired 
number of patients to the trial. According to the definition, Accrual period TAcc is given 
by  
TAcc = n/η                    Eq. I-1                       
Where n is sample size and η is accrual rate.  
Follow-up time TFU 
 Follow-up time TFU means the period starting from the end of accrual of scheduled 
number of patients for current trial to the beginning of the next one. It consists of the time 
for the current trial to be finished and analyzed. Generally, a follow up time of one year 
was considered.  
Number of trials K 
 The number of trials K conducted over the 15-year period was derived from the 
sample size, the expected annual accrual rate, and FU, i.e. the ratio of total research 
period to the length of each trial (Figure I-1). It follows that        
K =15/(TAcc+TFU ) = 15/(n/η+TFU)       Eq. I-2 
 
Figure I-1 Number of trials performed in a specific period 
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Hazard ratio HR 
 The hazard ratio HR of the hazard rate for treatment group (λE) to the control group 
(λS) is constant over time and derives from a known historical distribution with 
probability  10 /[1 +(21.87  log(HR)2)] and mean(HR)=0.95.10  
HRk = 
E
k
 k
S
/
  Eq. I-3 
 With a simple transformation from the above equation, we can easily find that the 
event rate λEk for the experimental treatment in the kth trial is proportional to the event 
rate Sk for the standard treatment in the kth trial. 
  Eq. I-4 
Level of statistical significance, α 
 α is the probability of wrongly concluding that two treatments A and B differ when 
in fact they do not differ. In our simulation, we considered the following α values: 2.5%, 
5%, 10%, 15%, 20%.  
  
Criteria for treatment selection and parameter evaluation 
 The experimental treatment will be selected when the following condition is 
satisfied: 
  Eq. I-5 
i.e. the treatment group has better treatment effect than the control group and the 
probability of the observed log-rank test statistic obtained from trial k is less than α. Here 
HRk is the estimated hazard ratio for trial k. F() denotes the cumulative distribution 
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function for a Chi-squared distribution with 1 degree of freedom (for 2 groups 
comparison) and χkLR is the observed log-rank test statistic obtained from trial k.  
 If the kth trial the experimental treatment is selected, it would be the standard 
treatment for the next trial: λsk+1 =HRk·λsk; if not, then the standard treatment in the kth 
trial is retained for the (k+1)th trial:  
λsk+1 =λsk   Eq. I-6 
 Let HRck+1 be the hazard ratio between the standard treatment of the (k+1)th trial 
and the standard treatment of the kth trial:  
HRck+1=λsk+1/λsk   Eq. I-7 
 Let HRO be the overall hazard ratio of the treatment event rate after series of K 
trials at the end of the 15 years to the event rate of the standard treatment of the first trial: 
HRO = λsk+1/λs1=∏HRck+1. We estimated the expected value of the overall hazard ratio 
(E(HRO)) by computing the mean of the observed distribution. 
 The probability of detrimental effect P(HRO > 1) , i.e. the event rate for the 
treatment selected at the end of the 15 years is worse than the event rate for the initial 
control group, is applied to evaluate the possibility of harm in the sensitivity analysis. 
 In our simulation, we will optimize the design parameters by considering the 
following two criteria: 1) minimization of E(HRo); 2) minimization of E(HRo) with the 
constraint P[HRo > 1] < 0.025. 
I-2.2  Simulations 
I-2.2.1  Scenarios 
 We considered 2 different disease settings (Scenarios) in 15 years as defined by 
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expected survival rates and different prevalence rates, which affects the yearly accrual 
rate (Figure I-2). 
Scenario 1 (Sc1) 
- The baseline survival curve was defined by the λs1 parameter:   
 Suppose the median survival is 1 year for the standard treatment and the survival 
distribution for each treatment follows an exponent function, thus we will have: 
Ss1(1 year) = 0.50 =>  λs1 = - ln(0.5)/1   Eq. I-8 
- Three accrual rates, , equal to 100, 200 or 500 patients / year, respectively. 
- Sample size increases from 100 to 1000 patients by 100 patients. 
- The minimal follow-up duration (TFU) has been set as 1 years. 
- Number of trials (K) performed in the 15 years was derived from sample size and 
accrual rate of each trial (n) according to the following relationship: 
K =15/(TAcc+TFU ) = 15/(n/η+TFU)   Eq. I-9 
Scenario 2 (Sc2) 
 This scenario with 6 months set-up period between two trials is used as sensitivity 
analysis to compare the treatment effects with scenario 1. 
- The baseline survival curve was defined by the λst parameter:    
 Suppose the median survival is 1 year for the standard treatment (see Eq. I-10) 
- Accrual rates, , equal to 100 patients / year. 
- Sample size equal to 100 patients. 
- The follow-up duration (TFU) has been set as 1 year. 
- The Set-up time (TSU) i.e. the length between end of a trial and start of the next one, 
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cannot be ignored and equals to 0.5 year. 
- Number of trials (K) performed in the 15 years was derived from sample size and 
accrual rate of each trial (n) according to the relationship 
K =15/(TAcc +TSU+TFU) = 15/(n/η+TSU+TFU)   Eq. I-11 
 
Figure I-2 Scenario 1 and 2 in our simulation 
 A total of 31 combinations of scenarios, accrual rate, number of trials that could 
reasonably be run over the 15 years were evaluated (Table I-1).   
Table I-1 List of the combinations between the baseline situation and the number of 
trials. 
Scenario Co 
Accrual 
rate η 
TFU 
Ss1 (1 
year) 
Number of 
patients n 
Accrual 
duration TACC 
Number 
of trials K 
1 1 100 1 0.5 1000 10 1 
1 2 100 1 0.5 900 9 1 
1 3 100 1 0.5 800 8 1 
1 4 100 1 0.5 700 7 1 
1 5 100 1 0.5 600 6 2 
1 6 100 1 0.5 500 5 2 
1 7 100 1 0.5 400 4 3 
1 8 100 1 0.5 300 3 3 
1 9 100 1 0.5 200 2 5 
1 10 100 1 0.5 100 1 7 
1 11 200 1 0.5 1000 5 2 
1 12 200 1 0.5 900 4.5 2 
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1 13 200 1 0.5 800 4 3 
1 14 200 1 0.5 700 3.5 3 
1 15 200 1 0.5 600 3 3 
1 16 200 1 0.5 500 2.5 4 
1 17 200 1 0.5 400 2 5 
1 18 200 1 0.5 300 1.5 6 
1 19 200 1 0.5 200 1 7 
1 20 200 1 0.5 100 0.5 10 
1 21 500 1 0.5 1000 2 5 
1 22 500 1 0.5 900 1.8 5 
1 23 500 1 0.5 800 1.6 5 
1 24 500 1 0.5 700 1.4 6 
1 25 500 1 0.5 600 1.2 6 
1 26 500 1 0.5 500 1 7 
1 27 500 1 0.5 400 0.8 8 
1 28 500 1 0.5 300 0.6 9 
1 29 500 1 0.5 200 0.4 10 
1 30 500 1 0.5 100 0.2 12 
2 31 100 1.5 0.5 100 1 6 
Co: number of the combination; 
 
I-2.2.2  Data Simulations 
 To study the treatment effects of various scenarios and accrual patterns, we 
simulated 5000 15-year research course clinical trials for each of the 31 different 
combinations as described in Table I-1. The study was performed using R version 3.1.2. 
We used R library survival to conduct the log-rank test and Cox proportional hazard ratio 
modeling while R programming language was used to simulate the data. 
 In each trial, the accrual of the patients was assumed to follow a uniform process 
over the time period TAcc. The patients were then randomized at a 1:1 ratio into the 
standard and the experimental groups. When the last enrolled patient had been followed 
up for a length of time TFU, the analysis was performed. Here, we assumed no patient 
dropouts and patients who survive the date of analysis were defined as right censored. 
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The event rate of the standard treatment group (S) of the first trial S1 is defined by 
disease scenario (Ss1 (1 year) = 0.5). The event rate in the Ek experimental treatment 
group (E) is derived from the randomly selected hazard ratio from the historical survival 
distribution. The event rate of the standard treatment group (S) Sk in the kth trial (k > 1) 
of successive trials is determined by the result of the log-rank test of the survival 
distribution between the control and the experimental treatment in the previous trial. 
After the series of K trials at the end of the 15-year period, the overall hazard ratio (HRO) 
and probability of detrimental P[HRo > 1] to assess the performances of the design 
parameters. 
I-3  Results 
I-3.1  Effect of the number of trials and α values on the expected mean 
overall hazard ratio E(HRo) 
 The expected overall hazard ratio simulated under scenarios 1 and 2 are reported in 
Table I-2 and Figure I-3. From these tables, we can easily observe the following trend: 
 First, the expected overall hazard ratio E(HRo) decreases monotonically when α 
value increases from 2.5% to 20% under accrual rates η=100, 200 and 500 patients per 
year, respectively (scenario 1). This trend is remarkably clear when the trial number is 
relatively large, which corresponds to a relatively small sample size for each trial. It is 
worth to note that there was very little improvement on relaxing the ɑ value when the 
number of trials K is small, i.e. a relatively large sample size. For example, when accrual 
rate η=100 patients per year and sample size is 900 patients, the expected overall hazard 
ratios fluctuate between 0.863 to 0.873 under various α values. Similarly, we also observe 
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the trend of decreased hazard ratio with increased ɑ value for scenario 2. To evaluate the 
treatment effect of scenario 2, we compare its expected overall hazard ratio with trials in 
scenario 1 that share the same accrual rate (η=100 patients per year) and number of 
patients (n =100) (Error! Reference source not found.). It was found that the addition 
of a set-up time to the trial decreased the expected overall hazard ratio, which clearly 
demonstrates that the more trials that carried out in a given time, the less overall hazard 
ratio will be expected. 
 Second, as illustrated above, the expected overall hazard ratio E(HRo) decrease 
monotonically when the number of trials increases for a given α value (Table I-2 and 
Table I-3). The minimized overall hazard ratio E(HRo) for each treatment is identified 
where the number of trials K is largest under accrual rate η=100 and 200 patients per year. 
When accrual rate increased to a certain degree like η= 500 patients per year in scenario 1 
(that also means larger sample size), the minimized overall hazard ratio E(HRo) is not 
always the largest one for all the α values (Table I-4). However, the trend is there, i.e. the 
minimized overall hazard ratio E(HRo) located in the area where the number of trials K 
was relatively larger. 
Table I-2 Observed mean of the Hazard Ratio HRo at 15 years, E(HRo) for scenario 1 
with an accrual rate η = 100 pts/yr 
α 
Value 
K, Number of trials (number of patients) 
1 (1000) 1 (900) 1 (800) 1 (700) 2 (600) 2 (500) 3 (400) 3 (300) 5 (200) 7 (100) 
0.025 0.871 0.873 0.883 0.883 0.782 0.806 0.710 0.726 0.632 0.616 
0.05 0.881 0.864 0.873 0.870 0.763 0.774 0.700 0.710 0.601 0.592 
0.1 0.870 0.863 0.871 0.865 0.768 0.772 0.676 0.698 0.579 0.526 
0.15 0.859 0.865 0.864 0.876 0.747 0.757 0.678 0.684 0.571 0.500 
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*The column in bold denote the lowest value of E(HRf) in a row, defining the number of 
trials K minimizing E(HRo) for each treatment selection criterion. 
Table I-3 Observed mean of the Hazard Ratio HRo at 15 years, E(HRo) for scenario 1 
with an accrual rate η = 200 pts/yr 
α 
Value 
K, Number of trials (number of patients) 
1 (1000) 1 (900) 1 (800) 1 (700) 2 (600) 2 (500) 3 (400) 3 (300) 5 (200) 7 (100) 
0.025 0.764 0.761 0.693 0.676 0.691 0.643 0.584 0.551 0.549 0.512 
0.05 0.774 0.770 0.670 0.662 0.686 0.606 0.558 0.497 0.518 0.486 
0.1 0.756 0.749 0.657 0.660 0.680 0.588 0.534 0.504 0.470 0.442 
0.15 0.760 0.730 0.665 0.642 0.654 0.580 0.515 0.489 0.465 0.401 
0.2 0.741 0.751 0.660 0.645 0.672 0.569 0.497 0.479 0.444 0.359 
*The column in bold denote the lowest value of E(HRf) in a row, defining the number of 
trials K minimizing E(HRo) for each treatment selection criterion. 
Table I-4 Observed mean of the Hazard Ratio HRo at 15 years, E(HRo) for scenario 1 
with an accrual rate η = 500 pts/yr 
α 
Value 
K, Number of trials (number of patients) 
1 (1000) 1 (900) 1 (800) 1 (700) 2 (600) 2 (500) 3 (400) 3 (300) 5 (200) 7 (100) 
0.025 0.514 0.536 0.537 0.496 0.507 0.464 0.424 0.433 0.441 0.500 
0.05 0.508 0.524 0.517 0.473 0.476 0.432 0.412 0.395 0.425 0.429 
0.1 0.502 0.508 0.517 0.447 0.461 0.410 0.389 0.372 0.370 0.368 
0.15 0.491 0.496 0.490 0.459 0.452 0.397 0.361 0.337 0.330 0.333 
0.2 0.496 0.482 0.504 0.438 0.437 0.403 0.349 0.337 0.326 0.312 
*The column in bold denote the lowest value of E(HRf) in a row, defining the number of 
trials K minimizing E(HRo) for each treatment selection criterion. 
Table I-5 Observed mean of the Hazard Ratio HRo at 15 years, E(HRo) for scenario 2 
with an accrual rate η = 100 pts/yr 
HRo α Value 
0.025 0.05 0.1 0.15 0.2 
0.2 0.864 0.867 0.873 0.877 0.742 0.754 0.673 0.676 0.538 0.479 
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E(HRo) 0.679 0.623 0.592 0.553 0.536 
E(HRo)* 0.616 0.592 0.526 0.500 0.479 
*The column in bold denote the lowest value of E(HRf) in a row, defining the 
number of trials K minimizing E(HRo) for each treatment selection criterion. 
E(HRo)* is excerpted data from Table I-2 that has the same accrual rate (η) 
and number of patients n. 
 
Figure I-3 The expected mean overall hazard ratio E(HRo) as functions of the number of 
patients (number of trials K) and α values for the disease scenario 1 (median survival = 1 
year, FU = 1 year) 
I-3.2  Effect of the number of trials and α values on the expected median 
overall hazard ratio med(HRo) 
Since the distribution of HRo is not normal, we also calculated the median of the 
overall hazard ratio to summarize the simulated treatment effect. The number of trials and 
the α value have showed a similar effect on the expected median overall hazard ratio 
med(HRo) (see Error! Not a valid bookmark self-reference.-Table I-9, and Figure I-
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4). The least median overall hazard ratio med(HRo) occur where the maximized number 
of trials K were achieved for each specified α value. From a series of simulations with the 
same number of trials and number of patients at the same accrual rate, we have found that 
the expected median overall hazard ratio monotonically decreases with larger α levels. 
These results clearly prove that the smallest trials are associated with the smallest 
expected hazard ratio, i.e. the best treatment effect. 
Table I-6 Observed the median Hazard Ratio HRo at 15 years, Med(HRo) for scenario 1 
with an accrual rate η = 100 pts/yr 
α 
Value 
K, Number of trials (number of patients) 
1 (1000) 1 (900) 1 (800) 1 (700) 2 (600) 2 (500) 3 (400) 3 (300) 5 (200) 7 (100) 
0.025 1.000 1.000 1.000 1.000 0.854 1.000 0.755 0.784 0.639 0.595 
0.05 1.000 1.000 1.000 1.000 0.844 0.826 0.735 0.739 0.595 0.564 
0.1 1.000 1.000 1.000 1.000 0.841 0.828 0.708 0.737 0.580 0.485 
0.15 1.000 1.000 1.000 1.000 0.811 0.814 0.707 0.722 0.573 0.466 
0.2 1.000 1.000 1.000 1.000 0.795 0.796 0.718 0.714 0.517 0.452 
*The column in bold denote the lowest value of Med(HRf) in a row, defining the number 
of trials K minimizing Med(HRo) for each treatment selection criterion. 
Table I-7 Observed the median Hazard Ratio HRo at 15 years, Med(HRo) for scenario 1 
with an accrual rate η = 200 pts/yr 
α 
Value 
K, Number of trials (number of patients) 
1 (1000) 1 (900) 1 (800) 1 (700) 2 (600) 2 (500) 3 (400) 3 (300) 5 (200) 7 (100) 
0.025 0.823 0.816 0.730 0.718 0.740 0.654 0.569 0.514 0.510 0.458 
0.05 0.844 0.821 0.699 0.684 0.724 0.619 0.559 0.463 0.481 0.424 
0.1 0.802 0.793 0.689 0.690 0.719 0.593 0.519 0.474 0.428 0.379 
0.15 0.811 0.776 0.692 0.668 0.682 0.583 0.507 0.460 0.424 0.322 
0.2 0.811 0.807 0.687 0.679 0.723 0.576 0.472 0.449 0.415 0.285 
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*The column in bold denote the lowest value of Med(HRf) in a row, defining the number 
of trials K minimizing Med(HRo) for each treatment selection criterion. 
Table I-8 Observed the median Hazard Ratio HRo at 15 years, Med(HRo) for scenario 1 
with an accrual rate η = 500 pts/yr 
α 
Value 
K, Number of trials (number of patients) 
1 (1000) 1 (900) 1 (800) 1 (700) 2 (600) 2 (500) 3 (400) 3 (300) 5 (200) 7 (100) 
0.025 0.480 0.514 0.530 0.454 0.483 0.426 0.362 0.388 0.361 0.434 
0.05 0.501 0.514 0.494 0.437 0.436 0.387 0.365 0.342 0.351 0.353 
0.1 0.486 0.480 0.510 0.420 0.418 0.376 0.339 0.330 0.317 0.291 
0.15 0.478 0.471 0.476 0.432 0.417 0.354 0.317 0.276 0.280 0.258 
0.2 0.475 0.469 0.493 0.393 0.404 0.357 0.299 0.271 0.272 0.254 
*The column in bold denote the lowest value of Med(HRf) in a row, defining the number 
of trials K minimizing Med(HRo) for each treatment selection criterion.  
Table I-9 Observed the median Hazard Ratio HRo at 15 years, Med(HRo) for scenario 2 
with an accrual rate η = 100 pts/yr 
HRo 
α Value 
0.025 0.05 0.1 0.15 0.2 
Med(HRo) 0.736 0.628 0.583 0.525 0.506 
Med(HRo)* 0.595 0.564 0.485 0.466 0.452 
*The column in bold denote the lowest value of Med(HRf) in a row, defining the number 
of trials K minimizing Med(HRo) for each treatment selection criterion. Med(HRo)* is 
excerpted data from Table I-6 that has the same accrual rate (η) and number of patients n. 
  16 
 
Figure I-4 The expected median overall hazard ratio Med(HRo) as functions of the 
number of patients (number of trials K) and α values for the disease scenario 1 (median 
survival = 1 year, FU = 1 year) 
I-3.3  Effect of the number of trials and α values on the probability of a 
detrimental effect P(HRO > 1) 
The probability of a detrimental effect P(HRo > 1) is the chance that the hazard rate 
for the new treatment chosen at the end of the 15 years is less effective than the hazard 
rate for the initial control treatment. The relationship between the probability of a 
detrimental effect P(HRo > 1), the number of trials and α values is summarized in Table 
I-10-Table I-13, and Figure I-5. From Table I-10, we can easily find that all trials under 
scenarios 1 and 2 have probability of a detrimental effect less than 1%. It looks like that 
this happens where the sample size decreases (or K increases) or α values turn to bigger. 
Since the probability of a detrimental effect in all cases is less than our expected value 
  17 
2.5%, we will not consider this indicator in the following step to find the optimal design 
parameter. 
Table I-10 Probability of a detrimental effect P(HRO > 1) at 15 years, for scenario 1 with 
an accrual rate η = 100 pts/yr 
α 
Value 
K, Number of trials (number of patients) 
1 (1000) 1 (900) 1 (800) 1 (700) 2 (600) 2 (500) 3 (400) 3 (300) 5 (200) 7 (100) 
0.025 0 0 0 0 0 0 0 0 0 0.001 
0.05 0 0 0 0 0 0 0 0 0 0 
0.1 0 0 0 0 0 0 0 0 0 0.002 
0.15 0 0 0 0 0 0 0 0 0 0 
0.2 0 0 0 0 0 0 0 0 0 0 
 
Table I-11 Probability of a detrimental effect P(HRO > 1) at 15 years, for scenario 1 with 
an accrual rate η = 200 pts/yr 
α 
Value 
K, Number of trials (number of patients) 
1 (1000) 1 (900) 1 (800) 1 (700) 2 (600) 2 (500) 3 (400) 3 (300) 5 (200) 7 (100) 
0.025 0 0 0 0 0 0 0 0 0 0 
0.05 0 0 0 0 0 0 0 0 0 0.002 
0.1 0 0 0 0 0 0 0 0 0.001 0.003 
0.15 0 0 0 0 0 0 0 0 0 0.002 
0.2 0 0 0 0 0 0 0 0.001 0.001 0 
 
Table I-12 Probability of a detrimental effect P(HRO > 1) at 15 years, for scenario 1 with 
an accrual rate η = 500 pts/yr 
α 
Value 
K, Number of trials (number of patients) 
1 (1000) 1 (900) 1 (800) 1 (700) 2 (600) 2 (500) 3 (400) 3 (300) 5 (200) 7 (100) 
0.025 0 0 0 0 0 0 0 0 0 0 
  18 
0.05 0 0 0 0 0 0 0 0 0 0.002 
0.1 0 0 0 0 0 0 0 0 0 0 
0.15 0 0 0 0 0 0 0 0 0 0 
0.2 0 0 0 0 0 0 0 0 0.001 0.001 
 
Table I-13 Probability of a detrimental effect P(HRO > 1) at 15 years, for scenario 2 with 
an accrual rate η = 100 pts/yr 
HRo 
α Value 
0.025 0.05 0.1 0.15 0.2 
P(HRo > 1) 0.000 0.000 0.001 0.000 0.000 
P(HRo > 1)* 0.001 0 0.002 0 0 
P(HRO > 1)* is excerpted data from Table I-10 that has the same 
accrual rate (η) and number of patients n. 
 
Figure I-5 The probability of detrimental effect P(HRo>1) as functions of the number of 
patients (number of trials K) and α values for the disease scenario 1 (median survival = 1 
year, FU = 1 year) 
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I-3.4  Search for the optimal design parameter in the different combinations 
of situations 
 We have shown in the above section that the treatment effect is related to α values 
and the number of trials K accomplished in the 15-year time period. The latter determined 
the trials’ sample sizes. In our simulation, we have set up two criteria to optimize the 
design parameters by considering: 1) minimization of E(HRo); 2) minimization of E(HRo) 
with the constraint P[HRo > 1] < 0.025. Since the constraint in the latter criteria is 
always satisfied in our scenarios, the two rules could be merged as one, i.e. to find the 
combination of a value and K that yields the lowest expected overall hazard ratio at 15 
years.  
 Let’s suppose that there is a clinical trial under the historical distribution having a 
one year median survival as the baseline and an accrual rate of 100 patients/year, we can 
find that the optimal design parameters with least mean overall hazard ratio E(HRo) 
0.479 are the combination of an α values equal to 20% and the number of trials K equal to 
7. The corresponding median overall hazard ratio is 0.452 and the probability of a 
detrimental effect is 0. When the accrual rate is improved to 200 patients/year without 
changing other settings, the optimal design parameters with least mean overall hazard 
ratio E(HRo) 0.359 are the combination of an α values equal to 20% and the number of 
trials K equal to 10. The corresponding median overall hazard ratio is 0.285 and the 
probability of a detrimental effect is 0. When the accrual rate is further increased to 500 
patients/year with other settings being the same, the optimal design parameters with least 
mean overall hazard ratio E(HRo) 0.312 are the combination of an α values equal to 20% 
and the number of trials K equal to 12. The corresponding median overall hazard ratio is 
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0.254 and the probability of a detrimental effect is 0.1%. It worth to mentioned that some 
cases exist that the minimized mean overall hazard ratio E(HRo) is not associated with 
the largest number of trial at certain α level when the accrual rate is equal to 500 
patients/year. Thus, to get best optimized result, the design parameters should be 
evaluated for each disease setting and each accrual rate. Our studies have clearly shown 
that the optimal design parameters by treatment effect is achieved when simulations with 
the greatest possible number of trials are available. Consider each disease scenario as a 
whole, we could find that the increase of accrual rate from 100 patients/year to 500 
patients/year at the same significance level lead to a substantial decrease the mean overall 
hazard ratio E(HRo) from 0.452 to 0.312 while no obvious change of the probability of a 
detrimental effect.  
I-4  DISCUSSION 
 We investigated the treatment effect of clinical trials with small sample size by 
simulation of various combinations of different accrual patterns and α significant levels 
under historical distribution over a longer research horizon. We evaluated the treatment 
effect with three metrics: the mean overall hazard ratio E(HRo), the median overall 
hazard ratio Med(HRo), and the probability of a detrimental effect P(HRo>1). We have 
found that the increase of accrual rate from 100 patients/year to 500 patients/year at the 
same significance level lead to a substantial decrease in the mean overall hazard ratio 
E(HRo) from 0.452 to 0.312 with no obvious change of the probability of a detrimental 
effect. By relaxing α values from 0.05 to 0.20 while the accrual rate is constant, the mean 
overall hazard ratio E(HRo) decrease monotonically. The optimal design parameters were 
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chosen based on the minimized mean overall hazard ratio E(HRo). Our calculated results 
show that smaller sample size, which corresponds to a larger number of trials, and larger 
α significant levels afford a better treatment effect according to the mean overall hazard 
ratio E(HRo) over a 15-year research period.  
 Some limitations exist in our study. First, we considered a constant accrual rate 
during the 15-year trial period. This might not be true and some highly variable accrual 
patterns might be presented in practice. Thus, the effect of fluctuated accrual rate on the 
treatment has not been evaluated. Secondly, our simulation relies on the Cox proportional 
regression model which assumes that a proportional hazard ratio between the control and 
the experiment groups applied in clinical trials with time-to event outcomes. In reality, 
the treatment effect might occur under non-proportional hazard ratio assumptions for the 
control and treatment groups of the study. We have also assumed that a new trial starts 
just after the previous trial is finished, and that the treatments between the control and the 
experiment groups are only different on the efficacy without considering the safety 
profiles of the treatment regimens. Our sensitivity analysis (scenario 2) shows that longer 
set-up time has some detrimental effect on the overall benefit at the end of 15 years but 
does not alter our conclusion.  
 In summary, we showed that accrual pattern and α values play an important role in 
clinical trials. In order to adapt to our increasingly small patient populations, we suggest 
that do a multitude of smaller trials with larger alpha values over an extended time period 
rather than traditional large trials.  
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Part II  Data Analysis of Histone 3 Lysine 36 Trimethylation 
ChIP-seq in Human Kidney Cancer 
II-1  Introduction 
 Chromatin immunoprecipitation (ChIP) coupled with high-throughput sequencing 
(ChIP-seq) is a powerful technique for genome-wide determination of the sites of 
transcription factor binding and histone modification. This chromatin-based assay has 
several steps (Figure II-1).11 The chromatin preparation step cross-links protein–DNA 
complexes in living cells with formaldehyde, quenches the reaction with glycine to 
prevent over-crosslinking, shears the DNA into approximately 100–200 base pair (bp) 
fragments by sonication or with micrococcal nuclease after cell lysis, and incubates with 
a specific antibody to pull down the targeted protein of interest (POI). The uncrosslinked 
and purified DNA fragments are then used for the library preparation as follows. The 
target-enriched DNA’s ends are blunted and added an “A” base to the 3’ end, which are 
ligated wiht an adapter bearing a 3’ T-overhang. The ChIP DNA is polymerase chain 
reaction (PCR) amplified, purified and sequenced on a next-generation sequencing 
platform. 
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Figure II-1 General procedures for preparation of ChIP library 
 The raw data processing involves the mapping/alignment of reads to the reference 
genome, normalization, identification of signal enriched regions (Peak calling), biological 
interpretation, and visualization of ChIP-seq results (Figure II-2). Generally, the 
majority of ChIP-seq reads are background, whose distribution differs across experiment 
methods, the genome locations and genome complexity. While peaks with strong signals 
are biologically most reproducible, it has been found that some modestly-enriched peaks 
also show high biological regulatory activity. 12  Experiments may also lead to the 
systematically underrepresented or over-represented signals in the ChIP-seq. To eliminate 
false positive (non-specific) peaks resulting from chromatin preparation, antibody cross-
reaction, PCR amplification, and mapping uncertainties in repetitive regions, a control 
DNA (input DNA or ChIP DNA from a nonspecific antibody) is usually needed to 
facilitate the bioinformatics analysis.13  
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Figure II-2 General workflow for the analysis of ChIP data 
 There are 3 major categories of profiles based on the range of ChIP-seq tag 
enrichment. Sharp peaks covering a few hundred base pairs or less, such as the binding 
sites of transcription factors, are relatively easy to identify and most algorithms available 
for peak calling are focusing on this class of binding; broad signals from some histone 
marks (e.g. histone 3 lysine 27 trimethylation (H3K27me3)) extend over several hundred 
kilobases.14 RNA Polymerase II produces a mixture of sharp and broad signals in a 
length up to a few kilobases.15 Here, we focus on histone modifications, as these present 
the most challenging case. To identify high confidence binding sites in a ChIP sample, 
peak calling algorithms calculating the enrichment of tag density over the background 
noise are applied. Normalization, which often sets the two samples to have the same total 
number of uniquely mappable tags, is critical to ensure that the enrichment is not biased 
toward a sample/region due to systematic errors. 
 Various studies have revealed that the background portion of the ChIP-seq/the 
control or different ChIP-seq samples show an approximate linear relationship.16 Thus 
most the studies calculated a normalization factor either by a linear scaling of read counts 
between samples or a linear regression of genomic densities, which is essentially 
equivalent to the linear scaling of all tags found in samples (Figure II-3). In essence, this 
method involves normalizing the immunoprecipitation (IP) data with the corresponding 
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control experiment (Input) by a scale factor s, which is defined as the ratio of the total 
number of background tags in IP to that in Input (Eq. II-1). The most commonly used 
strategy to estimate s is to divide the reference genome into non-overlapping bins with 
the width of w and sum the tags in each bin. Then the normalized number of local tags 
(or each bin) in Input could be obtained by multiplying the corresponding number of raw 
reads with the scale factor (Eq. II-2).  
s = NIP/NInput=∑nIPb∕∑nInputb   Eq. II-1 
n’Input = nInput x s   Eq. II-2 
  
Figure II-3 Normalization by background 
 Each approach employs a specific set of parameters to estimate the background tags 
in ChIP-seq. the differences between these methods lie in the choice of bin size and 
algorithm to determine background tags. Table II-1 summarizes the existing 
normalization methods. 
Table II-1 Commonly used normalization methods 
Methods Normalization parameter Merit/disadvantage Ref 
Sequencing 
depth 
scaling 
(SDS). 
Assuming all tags in 
ChIP-seq are background 
and signal in peaks are a 
small portion of the total 
tags. 
Enriching the background of 
peaks; untypical peaks are likely 
to lose information. 
17 
CisGen W=100 bp; nIPb≤1 Global parameter estimates; 18 
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improved spatial precision; 
untypical peaks are likely to lose 
information 
PeakSeq W=10000 bp; linear 
regression with a 
predefined p-value 
Local statistics; fewer false 
negatives; sensitive to outliers 
19 
NCIS Non-fixed window size; 
iteration for the first s 
larger than the previous 
one 
Untypical peaks are likely to 
lose information 
20 
MACS Window size of 1, 5 and 
10 kb 
Local statistics; fewer false 
negatives 
21 
 In this study we analyzed H3K36me3 (deposited by the chromatin regulator SETD2), 
an active mark associated with transcribed genes.22  
II-2  Data source 
 The ChIP-seq raw sequences for H3K36me3 and input DNA (human kidney cancer) 
were downloaded from EBI database. 23  The commands and the URLs used for 
downloading are shown in Figure II-4. 
wget ftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR351/ERR351382/ERR351382.fastq.gz 
wget ftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR351/ERR351359/ERR351359.fastq.gz 
wget ftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR351/ERR351366/ERR351366.fastq.gz 
wget ftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR351/ERR351380/ERR351380.fastq.gz 
Figure II-4  Commands for downloading the sequences 
 The information about the sequences is listed in the Table II-2. 
Table II-2 Sequence attribution 
Replicate Immunoprecipitate/input FASTQ.gz Total sequence tags 
1 
H3K36me3 (IP) ERR351382 53,826,161 
input ERR351359 37,459,480 
2 H3K36me3 (IP) ERR351366 37,903,732 
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input ERR351380 41,734,531 
 The Input samples for the two individuals are quite different: one produced roughly 
16 million fewer sequence tags while another one yield 4 million more sequence tags 
than the corresponding H3K36me3 IP samples. 
II-3  Workflow and result 
 All the software we used is publicly available. The computational platform is based 
on the high-performance computing cluster at Minnesota Supercomputing Institute of the 
University of Minnesota. The majority of the steps in this procedure is done from the 
command line in the Linux operating system environment.  
 Our data analysis involves three major steps: 1) Quality checking the sequence to 
ensure the analyzed tag is in good quality; 2) Map the raw reads back to a reference 
genome to identify the structure of sequences; 24  3) Peak calling to identify the 
differentiate real signal from noise by comparing with the control.25 
II-3.1  Quality Control Analysis to Assess Sequence Quality 
 To check the sequence run and ensure a good genome alignment, it is important to 
test the quality of raw sequence data, which will help to identify problems like low-
quality base pair or duplicates causing by adapter and primer during library preparation. 
The open source software FastQC (Babraham Bioinformatics)26 is one of the widely 
used software packages for this step. The result for the test is discussed below briefly. 
II-3.1.1  Per Base Sequence Quality 
 The boxwhisker plots here show the average (blue line), median (the central red 
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line) and inter-quartile range (25-75%, the yellow box) of the sequence quality score per 
base across all reads in a file. From the plots (Figure II-5), we could safely conclude that 
the base quality is pretty good: all bases are in the green region, which indicate very good 
quality calls. We have also observed that the quality of reads degrades as the run 
progresses as expected. 
 
Figure II-5 Per base sequence quality report generated from FastQC analysis. 
II-3.1.2  Per Sequence Quality  
 The per sequence quality plot is the distribution of the average quality per read, 
which could be used to determine subset of the reads with low score. Generally, when the 
average quality per read is below 20 (i.e. 1% error rate), it fails to pass the test. From the 
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plots (Figure II-6), we found that most reads of ChIP samples have an average quality of 
38 or 39, suggesting that the vast majority of reads had a good quality. 
 
Figure II-6 Per sequence quality report generated from FastQC analysis. Quality score 
distribution over all sequences for Input (B, D) and H3K36me3 (A, C). 
II-3.1.3  Per Base Sequence Content 
 If there is no pattern of special sequences (such as over represented sequence 
caused by PCR duplicates) presence, the probability of each base (A, T, G, and C) 
appearing at each position should be the same. Thus the base content across the sequence 
should be a straight line. In practice, the first few bases usually show some bias, probably 
due to the presence of not completely random adapters or primers. Usually, the test 
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determines the difference between the proportion of A and T, or C and G, if the value is 
greater than 10%, a warning would be given. When the value is over 25%, a failure alert 
would be issued. Our reports (Figure II-7) gave a difference around 10% across the 
length of the sequence tag except the first a few bases, indicating good quality of the 
reads.  
 
Figure II-7 Per base sequence content report generated from FastQC analysis. Sequence 
content across all bases for Input (B, D) and H3K36me3 (A, C). 
II-3.1.4  Per Sequence GC Content  
 Different genomic regions have different nucleotide compositions. The GC count 
per read across sequence reflects the GC content of the corresponding sequenced 
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genome.  In comparing the distribution of the sample to simulated theoretical 
distribution (its central peak denotes the overall GC content of the genome), if the two 
distributions deviate from each other, it implies that the library might be contaminated or 
contain a significantly over-represented sequence. A 15% deviation leads to a warning 
and over 30% deviation would fail to pass the test. From the reports of the analysis 
(Figure II-8), we found that all four samples passed the test.  
 
Figure II-8 Per sequence GC content report generated from FastQC analysis. GC content 
across each sequence for Input (B, D) and H3K36me3 (A, C). 
II-3.1.5  Per Base N Content  
 This test gave the percent of bases that could not be called by the sequencer across 
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the read. The threshold value for the test to issue a warning or failure alert is 5% or 20%, 
respectively. All samples passed this quality control test (Figure II-9 A-D) and only the 
first two sequences have a few bases that the sequencer could not identify.  
 
Figure II-9 Per base N content report generated from FastQC analysis. N content across 
all bases for Input (B, D) and H3K36me3 (A, C). 
II-3.1.6  Sequence Length Distribution  
 The Distribution of the length of the sequence tags describes the information of 
read length in each ChIP sample. This test tells issues such as early termination or 
mispriming during the sequencing run. Our results showed that the two sets of ChIP-seq 
have a read length at 50 and 36, respectively, and all samples were adequately sequenced 
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(Figure II-10 A-D). 
 
Figure II-10 Sequence length distribution report generated from FastQC analysis. 
Distribution of sequence lengths over all sequences for Input (B, D) and H3K36me3 (A, 
C). 
II-3.1.7  Sequence duplication levels 
 In order to reduce the computational requirements, this test only considers the first 
50 bases of a read across the first 100,000 reads within each file. If the first 50 bases 
between reads are the same, they will be deemed as identical (duplicates). The blue line 
on the report shows the distribution of duplication levels of the full 100,000 reads while 
the red line represents the distribution of the de-duplicated sequences. The duplication 
levels increased from diverse subsets to specific enrichment of subsets. The test will fail 
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with over 50% duplicates in the total sequence. Our report shows that all samples have 
passed this quality check (Figure II-11). 
 
Figure II-11 Duplicate sequence report generated from FastQC analysis. Sequence 
duplication levels for Input (B, D) and H3K36me3 (A, C). 
II-3.1.8  Over represented Sequences  
 This test gave information about adapter or primer related contamination. It 
examines the first 200,000 reads in each file and any similar sequences representing over 
0.1% of the total reads would be matched with a database of known sequencing primers 
and adapters. All samples have passed this test and no over represented sequences were 
observed. 
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II-3.1.9  Summary of FastQC analysis  
 The result of the FastQC test was summarized in Table II-3. All samples passed 
the check and are good enough for further analysis. 
Table II-3 Summary of FastQC analysis 
Analysis 
Sequence 
ERR351382 ERR351359 ERR351366 ERR351380 
Per Base Sequence Quality √ √ √ √ 
Per Sequence Quality √ √ √ √ 
Per Base Sequence Content √ √ √ √ 
Per Sequence GC Content √ √ √ √ 
Per Base N Content √ √ √ √ 
Sequence Length Distribution √ √ √ √ 
Sequence duplication levels √ √ √ √ 
Over represented Sequences √ √ √ √ 
II-3.2  Reads Alignment to the human genome 
 After quality control analysis, the next step is to align the short reads from each 
ChIP-seq and input sample to the human genome. Here we are using the Burrows-
Wheeler Alignment (BWA) tool (version 0.5.9), which represents a fast algorithm for the 
mapping of short-read data. This processing retains reads mapping to unique genomic 
loci and removes unmappable reads (such as divergent sequences or low-quality 
sequences) and reads aligning to multiple locations. The output BAM file contains 
strands, coordinates and other alignment information. 
 The detailed commands are shown below (Figure II-12), where human.fa 
represents the indexed human genome (hg19) generated by “bwa index -a bwtsw”. The 
command bwa aln aligns the reads according to the suffix array (SA) coordinates and 
produces a binary file input.sai, which could only be recognized by bwa samse. The 
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options “-o, -l, -t, -k, -m” denote maximum number of gap opens, seed length, number of 
threads, maximum edit distance in the seed (number of mismatched allowed), and 
maximum entries in the queue, respectively. The command samse is designed for the 
single-end reads, which transforms the SA coordinated input.sai to the chromosomal 
coordinated input.sam. The option -n represents the maximum number of alignments to 
output in the XA tag. The input.sam file was then transformed to its binary version 
(BAM) of Sequence Alignment/Map (SAM) file (smaller in size and faster in 
manipulation) by Samtools, which consists of a series of utilities that manipulate 
alignments in the BAM format including sorting, merging and indexing. The view 
command output sequence in the option specified format. The option -Shb specifies the 
input file type to be SAM (-S), including header in the output (-h) and specifying the 
output file type to be BAM (-b). The flagstat command provides 13 simple statistics like 
duplicates and mapping ratio on a BAM file. To get a unique read (a single read mapping 
to one best position), the view command was used. The option “-F 4 -q 20” extracts the 
mapped sequences (-F 4) with minimum mapping quality 20 (-q 20). The result was 
shown in Table II-4, with up to 98.7% reads mapped to the reference.  
bwa aln -o 1 -l 32 -t 4 -k 2 -m 50000000 indexed_human.fa input.fastq.gz >input.sai 
bwa samse -n 10 -f input.sam indexed_human.fa input.sai input.fastq.gz 
samtools-0.1.12a/samtools view -Shb input.sam > input.bam 
samtools flagstat input.bam 
samtools view -b -f 4 input.bam > unmapped.bam 
samtools view -b -F 4 file.bam > mapped.bam  
samtools view -h -F 4 -q 20 input.bam |samtools view -Sbh - > input.U1.bam 
samtools view -c input.U1.bam     
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Figure II-12 Commands for reads alignment 
Table II-4 Chip-Seq reads aligned to human genome 
Sample Total raw reads Mapped reads % Mapped 
Unmapped 
reads 
% 
Unmapped 
ERR351382 53,826,161 52,751,583 98.0% 1,074,578 2.0% 
ERR351359 37,459,480 36,308,272 96.9% 1,151,208 3.1% 
ERR351366 37,903,732 37,418,837 98.7% 484,895 1.3% 
ERR351380 41,734,531 40,990,915 98.2% 743,616 1.8% 
 Since Chip-seq data involves a PCR amplification process, it inevitably generates 
duplicates in the final sequences. Research has found that removing duplicate reads, i.e. 
keeping at most one read per genomic position at each strand, increases the significance 
of biological signals.27 Thus in the next step, Picard tools28 (Java-based command-line 
utilities) were used to manipulate the bam files. The command SortSam.jar sorts the bam 
file according to chromosome position (SO=coordinate) and the command 
MarkDuplicates.jar removes the duplicates in the bam. The parameters are set as 
following, and the sorted, deduplicated bam files were produced along with metrics files. 
The number of reads after duplicates removal are summarized in Table II-5 by samtool’s 
view command with -c option. Thus after removing duplicates, we had around 63-79% 
reads for peak calling. 
java -Xmx6g -Xms512m -jar picard/SortSam.jar INPUT=input.U1.bam 
OUTPUT=input.U1.sorted.bam MAX_RECORDS_IN_RAM=2000000 SO=coordinate 
TMP_DIR=working_directory VALIDATION_STRINGENCY=SILENT 
java -Xmx6g -Xms512m -jar picard/MarkDuplicates.jar INPUT=input.U1.sorted.bam 
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OUTPUT=input.U1.dedup.s1.bam METRICS_FILE=input.U1.sorted_metrics.txt 
REMOVE_DUPLICATES=TRUE ASSUME_SORTED=true 
VALIDATION_STRINGENCY=SILENT MAX_FILE_HANDLES=100 
TMP_DIR=working_directory/input_U1_dedup 
samtools view -c *.dedup.s1.bam    #count the number of reads 
samtools index *.dedup.s1.bam     #Index the bam files 
Figure II-13 Commands for removing duplicates 
Table II-5 Number of reads after removing duplicates  
Sequence 
Total 
sequence 
tags 
(fastq.gz) 
Mapped 
reads 
(U1.bam) 
De-duplicated 
reads 
(dedup.s1.bam) 
Duplicates 
Ratio 
(dedup/total) 
ERR351382 53826161 46245451 41007359 5238092 0.76 
ERR351359 37459480 31540709 29515907 2024802 0.79 
ERR351366 37903732 30064438 26800239 3264199 0.71 
ERR351380 41734531 33152881 26187116 6965765 0.63 
II-3.3  Detecting enriched regions 
 Once alignments were processed to remove unmapped reads and duplicates, peak 
calling algorithm was applied to identify binding sites (i.e. peaks). Most peak callers use 
p-value with or without false discovery rate (FDR) to evaluate the confidence of the 
identified peaks.29 Here, Sicer (Statistical model for Identification of ChIP-Enriched 
Regions), specifically designed for the analysis of histone modifications with broad 
occupancy like H3K36me3, was employed to find ChIP-enriched regions that are 
significantly different from a background by comparing ChIP read to a read count 
threshold derived from a Poisson process (Figure II-14).30 With input as the matched 
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control, SICER could further improve its accuracy in identifying the “candidate” islands. 
Since SICER requires BED formatted files as the input, BAM files were converted to 
BED format in the first step by using the command BamtoBed of the Bedtools suite.31 
The BED format is usually for storing annotations on genomic coordinates. The tab-
delimited columns record chromosome name, start position, end position, label, score, 
and strand. Then the bed files of Chip-seq were subjected to Sicer analysis. The files of 
IP.U1.dedup.s1.bam.bed and input.U1.dedup.s1.bam.bed correspond to the ChIP and 
input libraries. The key parameters are redundancy threshold (1 indicating that retaining 
only 1 read for each set of redundant or duplicate reads), window size (200 bps, default 
value set for histone modification), fragment size (200 bps for the average size of ChIP 
fragment, which determines the amount of shift (i.e. 100 bp) from the beginning of a read 
to the center of the DNA fragment), effective genome fraction (0.75, ratio of the 
mappable regions to the actual genome size), gap size (600 bps, multiple of window 
size), and FDR (1E-2, false discovery rate cutoff) for using a control library as 
background. TMPDIR is the output directory and hg19 specified the species and genome 
version analyzed. Once the analysis is done, Sicer would produce 10 output files. Of 
these files, the file *-FDR1E-2 contains detailed information (chromosome, start, end, 
read count in ChIP library, read count in control library, p-value, fold change, FDR) of 
identified islands with FDR less than 1% in the ChIP library, the bed file *-W200-G600-
FDR1E-2-island.bed is the redundancy-removed raw reads filtered by islands, and the 
wig file *-W200-G600-FDR1E-2-islandfilterednormalized.wig was used for visualization 
of the island-fitered ChIP library on a genome browser. The value of fold change reflects 
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the enrichment of Chip-seq to control (input). Here we identified peaks with fold change 
great than 2. By applying linux awk command, we first generated a 3-column file *-
FDR1E-2_3col.txt with the chromosome, start and end coordinate from the file *-
FDR1E-2. Since each line in the *-FDR1E-2_3col.txt file represent an identified peak, 
we can simply use linux command wc with option -l to obtain the number of peaks. To 
count the number of reads mapping to the peaks in the Chip-seq, the command intersect 
in the BEDTools was applied and the corresponding reads overlapped with the peaks was 
pipelined to samtools’ view command. The number of peaks identified and reads 
intersected with peaks in the Chip-seq were summarized in Table II-6 and Table II-7. 
We obtain 14,922 and 35,819 peaks respectively for the two sets of sequences. 
BEDTools/bamToBed -i input.U1.dedup.s1.bam > input.U1.dedup.s1.bam.bed 
SICER.sh TMPDIR IP.U1.dedup.s1.bam.bed input.U1.dedup.s1.bam.bed TMPDIR 
hg19 1 200 200 0.75 600 1E-2 
awk 'BEGIN {FS=OFS="\t"} {if($7>=2) print $1,$2,$3}' *-FDR1E-2>>*-FDR1E-
2_3col.txt 
wc -l *-FDR1E-2_3col.txt    # check number of peaks identified 
BEDTools/intersectBed -abam IP.U1.dedup.s1.bam -b Peak_file | samtools view -c – 
bedtools intersect -abam IP.U1.dedup.s1.bam -b *-FDR1E-2_3col.txt | samtools view –
c - >*_3colpeak_count 
head *_3colpeak_count       # check number of peaks identified 
Figure II-14 Commands for peak calling 
Table II-6 Number of identified peaks 
Sequence 
(IP.U1.dedup.s1.bam-W200-G600-
islands-summary-FDR1E-2_3col) 
Peaks 
identified 
Peaks with 
fold 
change >= 2 
ERR351382 (IP) 32,391 14,922 
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ERR351366 (IP) 52,662 35,819 
 
Table II-7 Number of reads in the peaks (Peaks with fold change >= 2) 
Sequence Number of reads 
ERR351382 (IP) 9,682,345 
ERR351359 (input) 2,806,622 
ERR351366 (IP) 6,959,694 
ERR351380 (input) 2,375,987 
 With reads count number in hand, we can easily calculate the ratio of reads mapped 
to peaks to the total unique reads in each Chip-seq. The ratio is greater than 0.2 for ChIP 
and around 0.1 for the control (Table II-8). 
Table II-8 Ratio of reads mapped to peaks to reads count in the Chip-seq 
Sequence 
Unique Reads in Chip-seq 
(dedup.s1.bam) 
Reads mapped to peak 
in Chip-seq 
Ratio 
ERR351382 (IP) 41,007,359 9,682,345 0.236 
ERR351359 (input) 29,515,907 2,806,622 0.095 
ERR351366 (IP) 26,800,239 6,959,694 0.259 
ERR351380 (input) 26,187,116 2,375,987 0.091 
II-3.4  Enriched regions through Normalization 
 Since the read count in the control is unlikely the same as the read count in the 
background of the Chip-seq library, the raw read counts have to be normalized first 
before further analysis.32 Normalization is an essential step to reduce the impact of noise, 
standardize the representation of data, and facilitate the identification of cluster structure 
in peak calling. A common method is to use the ratio of total reads or peak reads between 
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the ChIP and input samples for normalization. This estimation is often accompanied with 
bias. Here we will use the ratio of mapped reads within non-peak regions (they are true 
background) for normalization, which should increase the number of peaks and the fold-
change of peaks relative to the input. 
 Before normalization, we draw a scatter plot of the read counts in the Chip-seq 
library to that in the control library over pre-defined intervals. The purpose of this 
procedure is to check whether the library-size-based normalization is suitable. To do so, 
bin-level read count needs to be made. In the first step, the bam files of Chip-seq and 
input were converted into a tab-delimited 6-column bed file by setting the fragment size 
at 200 bp. This step was done by linux awk command. Then, the number of reads 
overlapping each of the 500-bp intervals of the human genome was counted. The 
recorded number of mapped reads (the fourth column) was transformed to a log2 scale to 
facilitate further manipulation. The detailed procedure is provided in the Figure II-15. 
samtools view *.s1.bam | \ 
awk 'BEGIN {FS="\t"; OFS="\t"} {if ($2 ==16) print $3,($4+ length($10) - 200),($4-
1+ length($10)),".","1","-"; else if ($2 ==0) print $3,$4,($4-1+ 200),".","1","+"}' | \ 
awk 'BEGIN {FS="\t"; OFS="\t"} {if ($2 <=0) print $1,"1",$3,$4,$5,$6; else print 
$0}' > *s1.bam.bed 
BEDTools /intersectBed -a hg19_24chr.w500.bed -b *s1.bam.bed -bed -wa -c | \ 
Awk 
'{printf("%s\t%d\t%d\t%d\t%.2f\t%.2f\n",$1,$2,$3,$4,log($4+1)/log(2),log(($4*10000
000/e5)+1)/log(2))}' > *s1.bam.bed.w500.count.tab   #e5 indicated the actual count 
in the *.s1.bam file 
Figure II-15 Commands for calculation normalization variable 
 With the data in hand, a scatter plot for each of the IP (x-axis) and input (y-axis) 
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pair was drawn (only Chr1 data was illustrated, Figure II-16). From the plots, we 
observed a large proportion of reads was in the enriched regions in both IPs. This 
indicates that normalization using peak-less reads should be more appropriate.  
  
Figure II-16 Scatter plot of IP to its corresponding input 
 To normalize according to the ratio of mapped reads within non-peak regions, we 
can calculate the normalization factor based on the following formula (Eq. II-3): 
NF=(IP_reads_count - IP_reads_in_Peak)/(INPUT_reads_count - 
INPUT_reads_in_Peak_matching_region) Eq. II-3 
Where IP_count and INPUT_count are the number of mapped reads in *.s1.bam; 
IP_Peak_count and INPUT_Peak_count are the number of mapped reads within peak 
regions. The result of the calculation was summarized in Table II-9. The normalization 
factors calculated are 1.172 and 0.833 for the replicates RR351382 (IP)/ERR351359 
(INPUT) and ERR351366 (IP)/ERR351380 (INPUT) respectively. 
Table II-9 Calculation of normalization factor 
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Data set IP count 
IP Peak 
count 
INPUT 
count 
INPUT 
Peak count 
NF 
1 41,007,359 9,682,345 29,515,907 2,806,622 1.172 
2 26,800,239 6,959,694 26,187,116 2,375,987 0.833 
 Data set: 1. ERR351382 (IP), ERR351359 (INPUT); 2. ERR351366 (IP), 
ERR351380 (INPUT) 
 With the normalization factor NF in hand, we can adjust the fold change in the peak 
files and calculate the number of peaks after the normalization accordingly. The 
commands we used are shown in the Figure II-17 and the result is summarized in Table 
II-10. It showed that the number of reads in the peak increased by 30.2% for sequence 
ERR351366 and 46.0% for ERR351382. 
awk 'BEGIN {FS=OFs="\t"} {print $0,$4/($5*NF)}' *islands-summary-FDR1E-2 > 
islands-summary-FDR1E-2.re.txt   
awk 'BEGIN {FS=OFs="\t"} {if ($7 >=2) print $0}' islands-summary-FDR1E-2 |wc –
l  #peaks before normalization 
awk 'BEGIN {FS=OFs="\t"} {if ($9 >=2) print $0}' islands-summary-FDR1E-2.re.txt 
|wc -l 
Figure II-17 Commands for normalizing the peak counts 
Table II-10 Enrichment after normalization 
Library IP Peak count 
before 
normalization 
IP Peak count 
after 
normalization 
Peak count 
change 
ERR351382 14,922 21,788 46.0% 
ERR351366 35,819 46,620 30.2% 
II-4  Conclusion 
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Chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) 
experiment is an important approach to determine the sites of protein-DNA interactions. 
It has been used to map transcription factor binding, RNA Polymerase II occupancy, and 
sites of chromatin regulators and histone modifications across cell types, tissues and 
conditions. To compare a ChIP sample with a control or another ChIP sample, the data 
has to be normalized to remove experimental biases. A widely used strategy involves 
linear scaling of number of uniquely mapped reads, which may not be well suitable for 
cases where the two libraries have very different enrichment levels.  
In this research, we have developed a general workflow for the analysis of publicly 
available histone 3 lysine 36 trimethylation (H3K36me3) data from human kidney cancer. 
By estimating the normalization factor only from background, we demonstrated the better 
performance of our method over the existing approach. An increase of peak counts of 
30%% and 46% were observed from the replicates we used. This approach is helpful for 
identifying reads that were otherwise ignored in the traditional SDS method. 
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